Kindred Biosciences — Investor Presentation (September 2014)
41 slides from Kindred Biosciences's investor presentation, Sep 24, 2014
Slide 1: KindredBio: Best Medicines for Our Best Friends
KindredBio Best Medicines for Our Best Friends
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including but not limited to statements regarding the timing of development for our product candidates, expected commencement and completion of pivotal trials, prospective product candidates, anticipated regulatory app
Slide 3: We Love Our Pet Family Members
We Love Our Pet Family Members $14.2 billion on veterinary care $1.5 billion on dog knee surgeries $370 million on pet Halloween costumes Annually, U.S. pet parents spend: 3
Slide 4: KindredBio mission
KindredBio Bring the very best science and medicine to our companion animals. Bring to dogs, cats, and other animals the same kind of humane, effective, and safe therapies that people enjoy. 4
Slide 5: Strategy: Repurpose Human Drugs for Pets
KindredBio Strategy: Repurpose Human Drugs for Pets Pursue molecules already known to work Reduce technical risk Reduce timelines $3M-$5M to develop each pet drug Reduce financing risk Portfolio approach 5
Slide 6: KindredBio Highlights
KindredBio Highlights Less than 2 Years to Launch AtoKin for atopic dermatitis in dogs SentiKin for post-operative pain in dogs 2+ launches per year thereafter Attractive Markets Rapidly growing Few current competitors World Class Team Extensive drug development experience Human and veterinary exper
Slide 7: World Class Leadership Team
Richard Chin, MD Founder and Chief Executive Officer Former Head of Clinical Research, BioTherapeutics, Genentech Rhodes Scholar World Class Leadership Team Stephen Sundlof, DVM, PhD Senior VP of Regulatory Affairs Former Director, Center for Veterinary Medicine, FDA Blake Hawley, DVM Chief Commerci
Slide 8: World Class Leadership Team (Directors)
World Class Leadership Team Ernest Mario, PhD Director Former CEO of Glaxo, Chairman & CEO of ALZA Chairman & CEO of Reliant Pharmaceuticals Ervin Veszprémi Director Former Head of Global Marketing, Novartis Animal Health Oleg Nodelman Director Managing Director, EcoR1 Capital Raymond Townsend
Slide 9: Product candidate pipeline
9/24/2014 9 Molecule Indication Formulation INAD Filed Clinical Study Filing of Rolling NADA Sections Small Molecule Product Candidates AtoKin – Second generation histamine antagonist Atopic dermatitis in dogs SentiKin – KCNQ potassium channel agonist Postoperative pain in dogs Postoperative pain in
Slide 10: Key Strengths
Key Strengths Validated, repurposed molecules Avoid risks associated with new chemical entities Reduced costs and timelines, including for API No royalties/milestones Expertise in biologics In-house clinical development capabilities Reduced costs and timelines by not having to rely on CROs Focus on
Slide 11: Market Opportunity
Market Opportunity 11
Slide 12: Veterinary Market is Growing Rapidly
Veterinary Market is Growing Rapidly The veterinary care market grew 54% from 2006 to 2013 In 2012, ~$2.7B was spent on pet therapeutics, our target segment Source: APPA & TriMark Vet Health Market, June 2013 $9.3 $14.2 $0 $2 $4 $6 $8 $10 $12 $14 $16 2006 2013 Sp e n d in g in B ill ion s 12
Slide 13: There is a High Willingness to Pay
There is a High Willingness to Pay… $500 $1,000 $2,000 $5,000 Extremely/Very likely 62% 42% 35% 22% Somewhat likely 18% 20% 28% 20% Not too likely/Not at all likely 18% 36% 36% 55% Don’t know 1% 2% 1% 3% Pet owners are willing to spend on their seriously ill pets if they require medical treatment So
Slide 14: But Treatment Options are Limited
…But Treatment Options are Limited Underserved market with attractive growth opportunities Few competing biotechs Large pharma focused on blockbusters On average, less than a dozen pet drugs are approved annually by the FDA In 2013 the FDA approved: 5 pet drugs 27 humans drugs 14
Slide 15: Veterinary Pharmaceuticals Field
Veterinary Pharmaceuticals Field We believe there are similarities between veterinary pharmaceutical field now and the human pharmaceutical field in its early stages: Similar regulatory standards Similar commercial and reimbursement landscape Similar development costs Numerous untapped opportunities
Slide 16: Veterinary vs. Human Markets
Veterinary vs. Human Markets Can reach market in 3-5 years Faster Development Lower Development Cost Almost no biotechs, almost no generics Lower Competition Self-Pay Very few reimbursement hurdles Can develop for $3M-$5M per product 16
Slide 17: Programs
Programs 17
Slide 18: KindredBio Strategy
KindredBio Strategy Small Molecule Already validated in humans & established manufacturing Customize species- specific dosage and formulate flavored/convenient delivery Biologics Targets based on approved human drugs (e.g., Enbrel and Orencia) Create canine/ feline/equine versions of biologics with
Slide 19: Canine Atopic Dermatitis Market
Canine Atopic Dermatitis Market Atopic dermatitis affects up to 10% of all dogs Dogs & their owners have poor quality of life Severe itching, hair loss, tearing of the skin, skin infection Some dogs require euthanasia Current therapies (steroids, cyclosporin, JAK2 inhibitor) effective but are immuno
Slide 20: AtoKin
AtoKin AtoKin (fexofenadine) is high-dose flavored, oral, chewable second generation antihistamine The active ingredient in AtoKin is approved for allergic diseases in humans and has a strong record of safety/efficacy AtoKin is not immunosuppressive, with potential use in both first-line and long-te
Slide 21: Effective in Canine Atopic Dermatitis
Effective in Canine Atopic Dermatitis The active ingredient in AtoKin is comparable to or better than steroids, the current standard of care 0 10 20 30 40 50 Pretreatment 3 weeks 6 week C A DESI S c or e Methylprednisolone Fexofenadine * * * + * p<0.05 vs. baseline, + p<0.05 in favor of fexofenadine
Slide 22: AtoKin: Pivotal Trial Status
AtoKin – Pivotal Trial Status Timeline: Pivotal trial initiated Plan to increase study size to increase power to >90%* This would reduce statistical risk from 20% to less than 10%, with only moderate increase in cost and timeline (results in mid-2015) File rolling NADA sections late 2014 - 2015 *pen
Slide 23: Post-Operative Pain Market
Post-Operative Pain Market Drugs approved for treatment of post-operative pain in dogs, NSAIDs and narcotics, have significant side effects Many dogs do not respond to NSAIDs NSAIDs can cause bleeding Fentanyl is a controlled narcotic and pets are often kept in the hospital while receiving it Fentan
Slide 24: SentiKin
SentiKin SentiKin (flupirtine) is a centrally acting non-opioid, non- NSAID, and non-steroidal analgesic The active ingredient in SentiKin is approved outside the United States for short-term treatment of pain in humans 24
Slide 25: SentiKin active ingredient efficacy vs tramadol
SentiKin The active ingredient in SentiKin has shown efficacy similar to tramadol in controlling pain in humans 0 1 2 3 4 5 6 7 Pretreatment Posttreatment P a in I n tensit y i n h u m a n s Tramadol Flupirtine Source: current Medical Research and Opinion (2008) 25
Slide 26: SentiKin: Pivotal Trial Status
SentiKin – Pivotal Trial Status Timeline: Pivotal trial initiated Plan to increase study size to increase power to >90% This would reduce statistical risk from 20% to less than 10%, with only moderate increase in cost and timeline (results in mid-2015) File rolling NADA sections late 2014 - 2015 26
Slide 27: SentiKin for Other Indications
SentiKin for Other Indications Post-operative pain in cats Osteoarthritis in dogs Post-operative pain in horses 27
Slide 28: KIND-010
KIND-010 Transdermal drug for inappetence in cats Completing formulation work PK studies under way Initiating pilot studies this quarter High unmet medical need Current drugs often not effective 90% of veterinarians treat cats with inappetence (average of 7 cats per week) 28
Slide 29: Biologics
Biologics Highly experienced biologics team Extensive experience developing Lucentis, Xolair, Tysabri, Avastin, Rituxan, Herceptin, Enbrel, and multiple other biologics Internal caninization/felinization/equinization expertise Pursuing strategies for fully canine/feline/equine antibodies, including
Slide 30: X-BODY Technology
X-BODY Technology B cells Antibody Gene Library Species Isoforms Epitope Steering Function 2-4 Rounds dsDNA Display Libraries Live Cell Selection Parallel Functional Selections Deep SequencingCDR3 Analysis FACS Analysis & Functional Screening Target Negative Proprietary technology to link antibody t
Slide 31: KIND-510 Feline Erythropoeitin
KIND-510 Feline Erythropoeitin Proprietary recombinant feline erythropoeitin Currently in cell line development Strong internal expertise in erythropoeitin biology and engineering High unmet medical need Up to 30% of elderly cats (over 15 years) develop kidney failure, leading to anemia Human erythr
Slide 32: Commercialization
Commercialization 32
Slide 33: Commercialization
Commercialization Option A: Launch and commercialize our U.S. products with ~50 person direct sales force Reach the top quartile of the highest prescribing veterinary clinics Use distributors to expand reach Top three national distributors responsible for fulfillment of approximately 70% of U.S. pet
Slide 34: Low Generic Penetration
Few pet generic companies No automatic substitution Requires sales & marketing effort Rimadyl reached peak sales several years after loss of exclusivity Low Generic Penetration Note: Companion Animal dispensing rate within the veterinary clinic. Source: IMS Health, Putney, BofA Merril Lynch Global R
Slide 35: Exclusivity and IP Position
Exclusivity and IP Position Full intellectual property protection for antibody portfolio Use and formulation patents for small molecules 20 years of patent protection from date of filing Regulatory Exclusivity 5 years in U.S. 10 years in E.U. Lifecycle Management New formulations, combinations and d
Slide 36: Business Development
Business Development In active discussions about acquisitions of businesses and/or assets Ideal candidate: Revenue generating/accretive Commercial infrastructure Complementary assets 36
Slide 37: Financing and Milestones
Financing and Milestones 37
Slide 38: Select Summary Financials
Select Summary Financials $ millions For the quarter ended June 30, 2014 Operating expenses: Research and development $5.6 General and administrative $2.5 Total cash operating expenses (excluding stock-based compensation) $6.9 Total operating expenses (including stock-based compensation) $8.1 Total
Slide 39: Milestones
Milestones Filed over 10 INADs Produced first canine biologic candidates Completed formulation development on CereKin/AtoKin Received two Protocol Concurrences (CereKin/AtoKin) Initiated CereKin pivotal study Initiate AtoKin pivotal study Initiate SentiKin pivotal study Announce pivotal data for Cer
Slide 40: Summary
Summary Validated Drugs and Targets $3M-$5M to Market Multiple Approvals Starting within 2 years World Class Team 40
Slide 41: Thank You
Thank You 41
Kindred Biosciences — Investor Presentation (September 2014) on 6ix